Breast cancer cells can evade the immune attack through a variety of complex mechanisms, among which tumor-derived immunosuppression resulting from upregulation of metabolistic enzymes, such as indoleamine 2,3-dioxygenase (IDO), has shown a crucial role in the recent studies [12–15]. This evidence concerns the gene IDO1 and neoplasm.